leadf
logo-loader
viewEvgen Pharma PLC
(
AIM:EVGFRA:8EV
)

Evgen Pharma: Johns Hopkins research further assesses the potential of company's drug to treat COVID-19

Scientists found that sulforaphane, the active ingredient in the company’s multi-purpose treatment, SFX-01, prevents virus-induced cell death sparked by variants of the SARS-CoV-2 virus and another unnamed coronavirus

Evgen Pharma PLC -

Work carried out by researchers at the world-famous Johns Hopkins in the US appears to underline the potential of Evgen Pharma PLC’s (LON:EVG) lead drug in battling Coronavirus (COVID-19).

Researchers found that sulforaphane, the active ingredient in the company’s multi-purpose treatment, SFX-01, prevents virus-induced cell death sparked by variants of the SARS-CoV-2 virus and another unnamed Coronavirus.

In addition, the Johns Hopkins team went on to demonstrate the drug inhibited toxicity to cells as a pre-treatment before inoculation while also acting “synergistically” with antiviral drug remdesivir.

Results from the lab-based work formed the basis of a recent pre-print publication that was released before it was peer-reviewed “given the urgency of the current pandemic”.

SFX-01 is being administered to treat people with severe COVID in the STAR clinical trial being carried out by scientists at Dundee University.

An interim analysis of the first hundred patients in the STAR study is expected sometime this quarter.

Of the Johns Hopkins update, Evgen chief executive, Huw Jones, said: “If the data continue to demonstrate efficacy after peer review, they underpin and support the hypothesis we are testing with the University of Dundee in the STAR COVID-19 clinical study.”

Quick facts: Evgen Pharma PLC

Follow
AIM:EVG

Price: 5.95 GBX

Market Cap: £16.36 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Evgen portfolio update on core field of cancer, 'the R&D is entirely on plan...

Evgen Pharma PLC's (LON:EVG) Dr Huw Jones joins Proactive London to go through their portfolio with progress for is lead asset on two fronts in the field of cancer. Jones firstly addresses the results of the ‘STAR’ Covid-19 trial of its lead asset, ‘SFX-01' which was implemented as an...

on 21/7/21

2 min read